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ORIGINAL ARTICLE
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms
of anxiety and depression, and health-related quality of life in moderate-to-severe
atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1
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ABSTRACT
Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly
improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-
severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized.
Objective: To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL.
Methods: Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1
(NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating
Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI),
Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension
EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness.
Results: Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p< .05), anxiety
and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p< .0001). At week
16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and
sleep, and no pain/discomfort (EQ-5D) (p< .0001).
Limitations: Cultural differences of translated PROs.
Conclusion: Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain,
anxiety and depression, and QoL in adults with moderate-to-severe AD.
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Introduction
Atopic dermatitis (AD) is a complex, chronic, systemic, inflamma-
tory skin disease characterized by erythematous, eczematous
lesions, and intense pruritus (1–4). Innate and adaptive immune
responses, and environmental factors, contribute to the clinical
presentation of AD (5,6). AD affects patients worldwide; the preva-
lence in adults is 4.4% in the European Union, 3.5% in Canada,
4.9% in the United States, and 2.1% in Japan (7).
AD adversely affects patients’ quality of life (QoL) (8–12).
Pruritus, a prominent symptom of AD, can be intense and debili-
tating (3,4,13) and is associated with reduced health-related QoL
(HRQoL) and increased incidence of depression and anxiety
(11,12,14,15). Rates of depression and suicidal ideation are higher
in patients with AD than in control populations (16–18), and
patients with AD report higher rates of pain, fatigue, insomnia,
and daytime sleepiness (9,19,20).
Moderate-to-severe AD in adults can be challenging to treat
because of the risk/benefit profiles of systemic therapies (21,22).
There is a substantial unmet need for safe and effective treatments,
especially for patients with inadequate response to currently avail-
able topical medications and systemic immunosuppressants (11,23).
Dupilumab is a fully human monoclonal antibody directed
against interleukin (IL)-4 receptor alpha (IL-4Ra), which inhibits sig-
naling of IL-4 and IL-13, cytokines that are key drivers of type 2 dis-
eases such as AD, asthma, allergic rhinitis, and food allergies,
diseases often associated as comorbidities (24). Dupilumab is
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approved for treatment of inadequately controlled, moderate-to-
severe AD in adults. In early and phase 3 clinical trials, including
SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), dupilumab sig-
nificantly improved, versus placebo, AD signs and symptoms in
adults with moderate-to-severe AD, and had a favorable safety pro-
file (12,25–28).
The burden of moderate-to-severe AD is not fully captured by
clinical outcome measures. To obtain further insight into the effi-
cacy of dupilumab, we evaluated its impact on patient-reported
symptoms of AD, including pruritus and sleep disturbance, anxiety
and depression, HRQoL, and global assessments of disease and
treatment effect using pooled data from SOLO 1 and 2.
Methods
Study design
The design and methodology of SOLO 1 (NCT02277743) and 2
(NCT02277769) have already been published (27). Briefly, SOLO 1
and 2 were randomized, placebo-controlled, double-blind, phase
3 trials. Eligible patients were aged  18 years and had AD for
 3 years, an Investigator’s Global Assessment (IGA) score of 3
(moderate) or 4 (severe), an Eczema Area and Severity Index
(EASI) score  16, and a pruritus Numerical Rating Scale (NRS)
average score  3. Patients received subcutaneous dupilumab
300mg once weekly (qw), or every 2 weeks (q2w), or placebo qw,
for 16weeks (27). Both trials were conducted in accordance with
the Declaration of Helsinki International Conference on
Harmonization, Good Clinical Practice guidelines, and applicable
regulatory requirements. All patients provided written informed
consent. Study oversight was provided by local institutional
review boards or ethics committees at each study site and by an
independent data and safety monitoring committee.
Patient-reported outcomes
Patient-reported outcomes (PROs) reported include least squares
(LS) mean percentage change from baseline to week 2 and per-
centage of patients with  3-point reduction from baseline
through week 16 in daily Peak Pruritus NRS score (29,30), (a pre-
specified secondary endpoint); percentage of patients reporting
‘absence of’/‘mild’ pruritus as well as ‘severe’ pruritus from base-
line through week 16 in Pruritus Categorical Scale (PCS) score
(31); LS mean change from baseline at week 2 and percentage of
patients at week 16 reporting absence of symptoms in the past
week in each Patient-Oriented Eczema Measure (POEM) item
(32,33); LS mean change from baseline at week 16 for patient-
reported Scoring AD (SCORAD) itch and sleep (34,35); LS mean
change from baseline at week 2 and week 16 in Hospital Anxiety
and Depression Scale (HADS) score (36,37); LS mean change from
baseline at week 2 and the percentage of patients reporting ‘not
at all’ at week 16 in Dermatology Life Quality Index (DLQI) score
(38,39); percentage of patients reporting ‘good,’ ‘very good,’ or
‘excellent’ through week 16 in Patient Global Assessment of
Disease Status (PGADS) and Patient Global Assessment of
Treatment Effect (PGATE); and on the five-dimension, three-level
EuroQoL questionnaire (EQ-5D) (40), the percentage of patients
reporting no pain or discomfort at week 16.
Peak Pruritus NRS measures the intensity of worst itch in the pre-
vious 24hours on a scale of 0–10; higher scores indicate more severe
pruritus. PCS measures intensity of itching, scratching, and/or discom-
fort due to pruritus in the previous 24hours on a four-point scale
(30). POEM assesses frequency of AD symptoms (itching, soreness, or
pain; redness of the skin, bleeding, weeping, or oozing of the skin;
dryness or roughness of the skin; flaking of the skin; cracking of the
skin; tightness of the skin) and impact of AD on sleep (32). The
HADS assesses symptoms of anxiety and depression with seven
questions for each, on a 0–3 scale (36). The DLQI has 10 questions
about the effect of AD on patients’ QoL during the previous week,
using a scale of (0–3) (39). The PGADS and PGATE are global assess-
ments of disease severity and treatment satisfaction, both on a five-
point scale. SCORAD visual analog scale (VAS) itch is a patient-
reported component of SCORAD. For VAS itch, patients report aver-
age itch for the past 3 days or nights. Sleep loss is assessed by
SCORAD VAS sleep—average sleep loss for the past 3 days or nights.
The EQ-5D is a standardized instrument for measuring QoL, with one
question for each of five dimensions: mobility, self-care, usual activ-
ities, pain or discomfort, and anxiety or depression (40).
Statistics
SOLO 1 and 2 data were pooled within each treatment group,
therefore all p values .05 are considered nominally significant.
All statistical tests were two-sided. For categorical endpoints, data
obtained after rescue medication use and missing data were con-
sidered ‘nonresponder’ data. For continuous endpoints, data
obtained after use of rescue medication and missing data were
accounted for using the last-observation-carried-forward method.
Statistical analyses were performed using SAS software, version
9.2 (SAS Institute, Inc., Cary, NC, USA). For comparisons of each
dupilumab dose with placebo according to the pre-specified hier-
archical order, a significance level of 0.025 was used, controlling
for the overall type I error rate at 0.05 for primary and secondary
endpoints. All reported p values are nominal, two-sided. Detailed
descriptions of the statistical analyses for the individual studies
are published elsewhere (27).
Results
Patients
In total, 1,379 patients were enrolled in the two studies. 457
patients received dupilumab 300 mg q2w, 462 received dupilu-
mab 300 mg qw, and 460 received placebo. In this pooled ana-
lysis, treatment groups had similar baseline demographics and
disease characteristics (Table 1).
Pruritus
Compared with placebo, dupilumab improved Peak Pruritus NRS
scores as early as day 2, regardless of dose regimen, with 4.5% LS
mean percentage change from baseline for dupilumab q2w,
p¼ .0033 vs. placebo; 4.0% for dupilumab qw, p¼ .0110 vs. pla-
cebo, and 0.6% for placebo; (Figure 1). More patients in the dupilu-
mab q2w and dupilumab qw groups had a 3-point improvement
in Peak Pruritus NRS score by day 4, compared with patients in the
placebo group (7.4% and 8.0%, respectively, vs. 3.3%; p¼ .0044 and
p¼ .0019, respectively, vs. placebo) and at weeks 2 and 16 (at week
2: 17.1% and 20.2%, respectively, vs. 5.1%; week 16: 48.8% and
50.3%, respectively, vs. 15.0% of placebo recipients; p< .0001 vs. pla-
cebo, either regimen at both time points; Table 2, Figure 1).
Dupilumab also rapidly improved itch severity as assessed on
the PCS. At week 2, more patients in the dupilumab q2w and
dupilumab qw groups reported ‘absent or mild’ pruritus, com-
pared with patients in the placebo group (29.1% and 30.7%,
respectively, vs. 13.9%; p< .0001 vs. placebo for either dose regi-
men; Table 2). At week 16, more dupilumab-treated patients
reported ‘absent or mild’ pruritus, compared with placebo (51.9%
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and 53.7%, respectively, vs. 19.3%; p< .0001 vs. placebo for either
dose regimen; Table 2). In addition, fewer dupilumab-treated
patients reported ‘severe pruritus’ at week 16, compared with pla-
cebo (20.8% and 21.9%, respectively, vs. 36.7%; p< .0001 vs. pla-
cebo for either dose regimen; Table 2).
For SCORAD VAS itch score, dupilumab-treated patients had a
higher LS mean change from baseline at week 16 than placebo-
treated patients (4.00 for dupilumab q2w, 4.06 for dupilumab
qw, and 1.26 for placebo; p< .0001, either regimen vs. placebo)
(Table 2).
Pain
Among patients reporting at least ‘some pain/discomfort’ on the
EQ-5D at baseline, more dupilumab- than placebo-treated
patients reported ‘no pain/discomfort’ at week 16 (45.7% for dupi-
lumab q2w, 43.2% for dupilumab qw, and 13.5% for placebo;
p< .0001 vs. placebo, either dose regimen; Table 2). Overall, by
week 16, 62.0–62.2% of dupilumab-treated patients reported ‘no
pain/discomfort,’ vs. 39.2% of placebo-treated patients, and
37.8–37.9% of dupilumab-treated patients reported ‘some/extreme
pain/discomfort,’ in contrast to 60.8% of placebo-treated patients.
Sleep
Dupilumab-treated patients (either regimen) had greater LS mean
change from baseline at week 16 in SCORAD sleep than placebo-
treated patients (3.3 for dupilumab q2w, 3.4 for dupilumab
qw, and 0.82 for placebo; p< .0001, either dose regimen vs. pla-
cebo; Table 2). At week 16 more dupilumab- than placebo-treated
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Figure 1. LS mean percentage change from baseline to week 2 in daily Peak Pruritus NRS score. Placebo, n¼ 460; dupilumab 300mg q2w, n¼ 457; dupilumab
300mg qw, n¼ 462. LS: least squares; NRS: Numerical Rating Scale; qw: weekly; q2w: every 2 weeks; SE: standard error.
Table 1. Baseline demographics and disease characteristics of patients in SOLO 1 and SOLO 2 (pooled data).
Characteristic Placebo (n¼ 460) Dupilumab 300mg q2w (n¼ 457) Dupilumab 300mg qw (n¼ 462)
Mean age, years (SD) 38.4 (14.0) 38.3 (14.4) 38.2 (14.5)
Male, n (%) 250 (54.3) 267 (58.4) 281 (60.8)
Race, n (%)
White 302 (65.7) 320 (70.0) 317 (68.6)
Black or African American 36 (7.8) 23 (5.0) 35 (7.6)
Asian 106 (23) 98 (21.4) 96 (20.8)
Other 8 (1.7) 8 (1.8) 8 (1.7)
AD duration, years (%) 28.8 (14.4) 27.9 (15.2) 27.6 (15.4)
BSA (%), mean (SD) 55.8 (23.3) 53.7 (22.2) 54.1 (22.3)
EASI total score, mean (SD) 34.0 (14.4) 32.4 (13.3) 32.5 (13.3)
IGA = 4, n (%) 225 (48.9) 223 (48.8) 218 (47.2)
Peak weekly averaged pruritus NRS score, mean (SD) 7.4 (1.8) 7.4 (1.8) 7.3 (1.9)
PCS score n (%)
‘absence of’/‘mild’ pruritus 40 (8.7) 32 (7.0) 37 (8.4)
‘moderate’ pruritus 197 (42.8) 218 (47.7) 193 (41.8)
‘severe’ pruritus 222 (48.3) 206 (45.1) 227 (49.1)
SCORAD total score, mean (SD) 68.8 (14.5) 67.1 (13.7) 67.5 (13.3)
POEM score, mean (SD) 20.6 (5.9) 20.3 (6.0) 20.7 (5.9)
DLQI score, mean (SD) 15.1 (7.5) 14.7 (7.3) 15.1 (7.5)
HADS total score, mean (SD) 13.2 (8.3) 13.0 (7.4) 13.7 (8.2)
GISS total score, mean (SD) 9.1 (1.8) 9.0 (1.8) 8.9 (1.7)
AD: atopic dermatitis; BSA: body surface area; DLQI: Dermatology Life Quality Index; EASI: Eczema Area and Severity Index; GISS: Global Individual Signs
Score; HADS: Hospital Anxiety and Depression Scale; IGA: Investigator’s Global Assessment; NRS: Numerical Rating Scale; PCS: Pruritus Categorical Scale;
POEM: Patient-Oriented Eczema Measure; qw: weekly; q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; SD: standard deviation.
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patients reported absence of sleep disturbance as assessed by
POEM (51.2%, 43.5%, and 17.6% for dupilumab q2w, dupilumab
qw, and placebo, respectively; p< .0001, either dose regimen vs.
placebo; Figure 2).
Patient-reported symptoms of AD
Compared with placebo, dupilumab rapidly improved AD symp-
toms as assessed by POEM. Significant improvement in POEM
scores was observed in dupilumab-treated patients as early as
week 2, with an LS mean change from baseline of –5.8 for dupilu-
mab q2w, –6.2 for dupilumab qw, and –1.6 for placebo (p< .0001
either dose regimen vs. placebo; Table 2). For all POEM items, at
week 16 a greater proportion of patients treated with dupilumab,
vs. placebo, reported having no symptoms during the past week
(p< .0001, either dupilumab dose regimen vs. placebo; Figure 2).
Symptoms of anxiety and depression
Both dupilumab dose regimens improved symptoms of anxiety
and depression as early as week 2, as assessed by HADS, com-
pared with placebo. Improvement was maintained through week
16 (p< .0001 both regimens vs. placebo; Table 2).
Table 2. Patient-reported outcomes in SOLO 1 and SOLO 2 (pooled data).
Placebo (n¼ 460) Dupilumab 300mg q2w (n¼ 457) Dupilumab 300mg qw (n¼ 462)
Peak Pruritus NRS: improvement, n/
N (%)a
 3 points from baseline at day 4 15/447 (3.3) 34/451 (7.4)b 37/445 (8.0)c
 3 points from baseline at week 2 23/447 (5.1) 77/451 (17.1)d 90/445 (20.2)d
 3 points from baseline at week 16 67/447 (15.0) 220/451 (48.8)d 224/445 (50.3)d
PCS score: n (%)e
Week 2
‘absence of’ or ‘mild’ pruritus 64 (13.9) 133 (29.1)d 142 (30.7)d
‘moderate’ pruritus 184 (40.0) 211 (46.2)f 200 (43.3)
‘severe’ pruritus 169 (36.7) 95 (20.8)d 101 (21.9)d
Week 16
‘absence of’ or ‘mild’ pruritus 89 (19.3) 237 (51.9)d 248 (53.7)d
‘moderate’ pruritus 74 (16.1) 102 (22.3) 78 (16.9)
‘severe’ pruritus 39 (8.5) 26 (5.7) 18 (3.9)g
POEM score: LS mean change from base-
line at week 2 (SE)
1.6 (0.27) 5.8 (0.27)d 6.2 (0.26)d
DLQI score: LS mean change from base-
line at week 2 (SE)
1.9 (0.25) 5.6 (0.25)d 5.7 (0.25)d
HADS score: LS mean change from base-
line at week 2 (SE)
0.8 (0.23) 2.9 (0.23)d 3.0 (0.23)d
HADS score: LS mean change from base-
line at week 16 (SE)
1.0 (0.28) 4.7 (0.28)d 5.0 (0.28)d
SCORAD VAS itch score: LS mean change
from baseline at week 16 (SE)h
1.26 (0.14) 4.00 (0.14)d 4.06 (0.14)d
SCORAD VAS sleep score: LS mean
change from baseline at week
16 (SE)i
0.82 (0.14) 3.30 (0.14)d 3.40 (0.14)d
EQ-5D: patients reporting no pain or dis-
comfort at week 16, n/N (%)j
49/362 (13.5) 169/370 (45.7)d 163/377 (43.2)d
PGADS: patients reporting their status as
‘good’ at week 16 n (%)
60 (13.0) 98 (21.4)k 102 (22.1)l
PGADS: patients reporting their status as
‘very good’ or ‘excellent’ at week 16
n (%)
53 (11.5) 174 (38.1)d 169 (36.6)d
PGATE: patients reporting their status as
‘good’ at week 16 n (%)
52 (11.3) 98 (21.4)d 85 (18.4)m
PGATE: patients reporting their status as
‘very good’ or ‘excellent’ at week 16
n (%)
45 (9.8) 199 (43.5)d 204 (44.2)d
DLQI: Dermatology Life Quality Index; EQ-5D: 5-dimension 3-level EuroQoL; HADS: Hospital Anxiety and Depression Scale; LS: least squares;
n/N: number of patients with outcome/total number of patients in this treatment group; NRS: Numerical Rating Scale; PCS: Pruritus
Categorical Scale; PGADS: Patient Global Assessment of Disease Status; PGATE: Patient Global Assessment of Treatment Effect; POEM: Patient-
Oriented Eczema Measure; qw: weekly; q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; SE: standard error; VAS: visual analog scale.
aAnalyses for patients with Peak Pruritus NRS score  3 were conducted on the subset of patients with baseline Peak Pruritus NRS  3.
b
p¼ .0044 vs. placebo.
c
p¼ .0019 vs. placebo.
d
p< .0001 vs. placebo.
eValues after first rescue treatment were set to missing (censoring).
f
p¼ .0166 vs. placebo.
g
p¼ .0035 vs. placebo.
hAnalysis for SCORAD itch was performed in patients from whom baseline data were collected: placebo, n¼ 440; dupilumab 300mg q2w,
n¼ 444; dupilumab 300mg qw, n¼ 449.
iAnalysis for SCORAD sleep was performed in patients from whom baseline data were collected: placebo, n¼ 440; dupilumab 300mg q2w,
n¼ 445; dupilumab 300mg qw, n¼ 449.
jAmong the subset of patients who reported at least some pain or discomfort on the EQ-5D at baseline (placebo, n¼ 362; dupilumab
300mg q2w, n¼ 370; dupilumab 300mg qw, n¼ 377).
k
p¼ .0003 vs. placebo.
l
p¼ .0007 vs. placebo.
m
p¼ .0026 vs. placebo.
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Health-related quality of life
Improvement in HRQoL, as assessed by the DLQI, versus placebo
occurred as early as week 2, with 5.6 LS mean change from base-
line for dupilumab q2w, 5.7 for dupilumab qw, and 1.9 for pla-
cebo (p< .0001 vs. placebo, either dose regimen; Table 2). At week
16, more dupilumab- than placebo-treated patients responded ‘not
at all’ to each item of the DLQI, indicating minimal impact on QoL
(p< .0001 vs. placebo, either dose regimen; Figure 2).
Global assessment of disease status and treatment effect
Patients’ impressions of their disease status, as measured by PGADS,
improved over time, with more patients in the dupilumab q2w and
qw groups reporting ‘very good or excellent’ status at week 16,
compared with placebo (38.1% and 36.6%, respectively, vs. 11.5%;
p< .0001 vs. placebo, either dose regimen; Table 2). Patients whose
baseline PGADS rating was ‘poor/fair’ showed rapid improvement,
with 43.9% and 45.3% of patients receiving dupilumab q2w, dupilu-
mab qw reporting ‘good,’ ‘very good,’ or ‘excellent’ status by week
2, vs. 17.7% of placebo recipients, as did 54.4% and 54.2%, respect-
ively, at week 16, versus 17.4% of placebo recipients (p< .0001 vs.
placebo, either dose regimen; Figure 3). In addition, more dupilu-
mab-treated patients reported a ‘good,’ ‘very good,’ or ‘excellent’
global treatment effect at each visit, as assessed by PGATE; 57.3%
and 58.0%, respectively, vs. 24.3% of placebo recipients at week 2,
to more than 70% of dupilumab-treated patients at week 6, and
with sustained improvement though week 16 (p< .0001 vs. placebo,
either dose regimen; Figure 3).
Safety
Safety data from the individual studies have been previously pub-
lished (27). Briefly, the incidence of adverse events was similar in
the dupilumab and placebo groups (27).
Discussion
In this pooled analysis of data from SOLO 1 and 2, dupilumab
treatment resulted in rapid improvement of multiple outcomes
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Figure 2. Patient-reported symptoms and Qol: percentage of patients reporting absence of symptoms in the past week in each POEM item at week 16 in SOLO 1
and 2 (pooled data), placebo, n¼ 460; dupilumab 300mg q2w, n¼ 457; dupilumab 300mg qw, n¼ 462; and percentage of patients reporting ‘not at all’ on individ-
ual DLQI items at week 16 in SOLO 1 and 2 (pooled data), placebo, n¼ 460; dupilumab 300mg q2w, n¼ 457; dupilumab 300mg qw, n¼ 462. DLQI: Dermatology
Life Quality Index; POEM, Patient-Oriented Eczema Measure; qw: weekly; q2w: every 2 weeks; QoL: quality of life.
JOURNAL OF DERMATOLOGICAL TREATMENT 5
important to patients, including pruritus, sleep disturbance, pain,
symptoms of anxiety and depression, and HRQoL.
The results presented here are noteworthy because patients
entering SOLO 1 and 2 had a substantial disease burden not con-
trolled by topical treatments. Before enrollment, 32.9% of patients
in SOLO 1 and 33.0% in SOLO 2 had received systemic glucocorti-
coids, and 25.9% and 31.4%, respectively, had received systemic
immunosuppressants (27). These pooled analyses confirm findings
from previous studies of dupilumab (25–28,41).
Pruritus has a considerable negative effect on patients’ HRQoL
and sleep (11,14,42,43). In a recent study, nearly 70% of patients
with moderate-to-severe AD reported pruritus caused sleep distur-
bances including delay falling asleep or waking at night (11).
Sleep deprivation negatively affects HRQoL and daily productivity
(42,43). Stronger itch intensity has been linked to increased stress
levels and depression (14).
The rapid improvement in itch observed in this study may
have a downstream effect on other aspects of disease burden, as
indicated by early responses assessed by POEM, DLQI, and HADS,
and previous reports that improvement in itch is positively corre-
lated with QoL improvement, as measured by DLQI (44).
Improvements in itch and sleep have been demonstrated by
other drugs for treatment of moderate-to-severe AD (45).
Significant improvement with dupilumab was seen not only in
composite measures but also in the individual components of the
DLQI and POEM, including improvement in itchy, painful, sore or
stinging skin, feelings of embarrassment, and reduced sleep dis-
turbance. The observed improvement in itch is also clinically
meaningful, defined as a within-person change of  3–4 points in
Peak Pruritus NRS score (46). This pooled analysis is the first to
demonstrate itch improvement as early as day 2 with dupilumab
treatment. This study also applied stringent criteria to determine
the effectiveness of dupilumab in improving AD symptoms and
QoL, measuring the percentage of patients with the absence of
symptoms in POEM and DLQI categories.
Dupilumab treatment has been reported to reduce pain and
discomfort (41). Pain has rarely been evaluated systematically in
AD studies, an important gap in characterizing the burden of AD
(9). Recent reports highlight pain as an important symptom in
patients with moderate-to-severe AD and support pain as a rele-
vant outcome in determining AD-related treatment response (47).
Future clinical trials in moderate-to-severe AD should administer
appropriate PRO scales to characterize the burden of AD-related
pain and enable evaluation of treatment efficacy in different
dimensions of pain.
The improvement in anxiety and depression measured by the
HADS anxiety and depression subscales reported for the individ-
ual SOLO trials (27), in addition to the improvement in overall
HADS scores reported here, suggests dupilumab reduces anxiety
and depression, symptoms prevalent among patients with AD
that increase the disease burden in patients with more severe dis-
ease (8). AD-related depression may be not only a secondary
comorbidity but also a symptom caused directly by inflammatory
cytokines, as suggested by recent evidence for the contribution of
inflammatory cytokines to the development of depression in gen-
eral medicine (48). Improving anxiety and depression in patients
with AD may potentially reduce their risk of suicidal ideation.
Global assessments provide a ‘real-world’ assessment of dis-
ease status and treatment effectiveness from the patient’s per-
spective, demonstrated by the rapid increase in satisfaction
among dupilumab-treated patients in this study, reported by the
PGATE and PGADS. In this analysis, this self-perceived improve-
ment was greater than 70% among dupilumab-treated patients.
In SOLO 1 and 2, among patients not reaching an IGA score of 0
or 1 at week 16, a greater proportion of dupilumab- than pla-
cebo-treated patients reported ‘good,’ ‘very good,’ or ‘excellent’
on the PGATE (49), demonstrating that physician assessments
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Figure 3. Percentage of patients reporting ‘good’, ‘very good’, or ‘excellent’ on the PGADS and PGATE through week 16 after reporting ‘poor’ or ‘fair’ at baseline in
SOLO 1 and 2 (pooled data). p< .0001 for both dupilumab regimens vs. placebo at all time points. Placebo, n¼ 460; dupilumab 300mg q2w, n¼ 457; dupilumab
300mg qw, n¼ 462. PGADS data is for patients reporting ‘poor’ or ‘fair’ at baseline. PGADS: Patient Global Assessment of Disease Status; PGATE: Patient Global
Assessment of Treatment Effect; qw: weekly; q2w: every 2 weeks.
6 M. J. CORK ET AL.
such as IGA might not fully capture disease status and treat-
ment efficacy.
A limitation to consider when interpreting these results is this
pooled analysis was not pre-specified; therefore, all p values
should be considered nominal.
In conclusion, dupilumab is not only clinically efficacious in AD
(27), but also demonstrates efficacy in a range of outcomes, with
significant, early-onset improvements in patient-reported AD
symptoms including itch, pain, sleep disturbance, anxiety and
depression, HRQoL, and patients’ assessment of disease status
and treatment effect versus placebo in moderate-to-severe AD.
These data expand upon previous reports by showing that dupilu-
mab improves AD in multiple dimensions important to the
patient and highlight the importance of PROs in assessing the
efficacy of treatments for AD.
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